U.S. markets open in 7 hours 33 minutes

Opiant Pharmaceuticals, Inc. (OPNT)

NasdaqCM - NasdaqCM Real Time Price. Currency in USD
Add to watchlist
13.90+0.08 (+0.58%)
At close: 4:00PM EDT

Opiant Pharmaceuticals, Inc.

233 Wilshirre Boulevard
Suite 280
Santa Monica, CA 90401
United States
310 598 5410

Full Time Employees30

Key Executives

NameTitlePayExercisedYear Born
Dr. Roger CrystalPres, CEO & Director920.58kN/A1976
Mr. David D. O'TooleChief Financial Officer618.95kN/A1959
Dr. Phil SkolnickChief Scientific Officer685.78k45.34k1947
Ben AtkinsVP of Communications & Investor RelationsN/AN/AN/A
Mr. Brian GormanGen. CounselN/AN/AN/A
Amounts are as of December 31, 2020 and compensation values are for the last fiscal year ending on that date. Pay is salary, bonuses, etc. Exercised is the value of options exercised during the fiscal year. Currency in USD.


Opiant Pharmaceuticals, Inc., a specialty pharmaceutical company, develops medicines for addictions and drug overdose. The company offers NARCAN nasal spray, a treatment to reverse opioid overdoses. Its pipeline of product candidates includes medicines for the treatment for opioid overdose reversal; alcohol use disorders; acute cannabinoid overdose; and opioid use disorders. The company was formerly known as Lightlake Therapeutics Inc. and changed its name to Opiant Pharmaceuticals, Inc. in January 2016. Opiant Pharmaceuticals, Inc. was incorporated in 2005 and is headquartered in Santa Monica, California.

Corporate Governance

Opiant Pharmaceuticals, Inc.’s ISS Governance QualityScore as of N/A is N/A. The pillar scores are Audit: N/A; Board: N/A; Shareholder Rights: N/A; Compensation: N/A.

Corporate governance scores courtesy of Institutional Shareholder Services (ISS). Scores indicate decile rank relative to index or region. A decile score of 1 indicates lower governance risk, while a 10 indicates higher governance risk.